The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) will go through yet another re-pricing after regulators performed confirmatory analyses on the results of its pilot cost-effectiveness assessment (CEA) program. However, its new NHI price and the effective date will not be disclosed…
To read the full story
Related Article
- Opdivo to Face CEA-Based Price Tweaks on Aug. 1
May 15, 2019
- Working Group Discussions Underway to Address Technical Issues for CEA before Confirmatory Analyses for 7 Products
May 18, 2018
- MHLW Proposes Working Group Discussions before Another Round of CEA Analyses for 7 Products: Chuikyo
March 8, 2018
- Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
March 8, 2018
- Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
REGULATORY
- Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
- Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
- Japan Hands Out Orphan Designation to 11 Drugs
December 24, 2025
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…